RecruitingAlzheimer DiseaseAlzheimer Disease (AD)Preclinical Alzheimer's Disease
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
Eligible age
40–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.
Sponsor: Nuravax, Inc.
You may qualify if…
- ✓ Healthy males and non-pregnant, non-lactating females, 40-65 years old
- ✓ BMI between 18.0 and 32.0 kg/m²
- ✓ Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI
- ✓ Signed informed consent
- ✓ Women of childbearing potential: negative pregnancy test and use of effective contraception
- ✓ Men: vasectomized or agree to use condoms / not donate sperm during the study period
You may not qualify if…
- ✕ Clinically significant medical or psychiatric illness that may affect safety or study results
- ✕ MRI abnormalities (e.g., infarcts, microbleeds, ARIA-E) or contraindications to MRI
- ✕ Significant lab abnormalities (e.g., liver, kidney, hematology) or positive HIV/HBV/HCV tests
- ✕ Uncontrolled blood pressure, abnormal heart rate, or prolonged QTc interval
- ✕ Recent serious illness, surgery, or investigational drug use within 30 days
- ✕ Prior amyloid-beta or tau immunotherapy within 1 year
- ✕ Use of immunosuppressive agents or chronic anticoagulants
- ✕ History of severe vaccine reactions, autoimmune disease, or significant allergies
Where it's recruiting
Florida
Miami Lakes
Source: ClinicalTrials.gov · NCT07142278 · last updated 2026-09-30